Seres Therapeutics, Inc.
MCRB
$9.31
-$0.77-7.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 64.00K | 374.00K | 126.85M | 126.33M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 64.00K | 374.00K | 126.85M | 126.33M |
| Cost of Revenue | 47.66M | 45.55M | 47.34M | 76.25M | 98.52M |
| Gross Profit | -47.66M | -45.55M | -47.34M | 50.22M | 27.43M |
| SG&A Expenses | 56.70M | 58.22M | 64.94M | 76.93M | 83.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -171.00K | -171.00K | -171.00K | 4.52M | 5.71M |
| Total Operating Expenses | 128.94M | 137.13M | 152.54M | 198.15M | 228.61M |
| Operating Income | -128.94M | -137.13M | -152.54M | -71.67M | -102.65M |
| Income Before Tax | -139.68M | -158.76M | -148.74M | -69.31M | -100.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -139.68 | -158.76 | -148.74 | -69.31 | -100.35 |
| Earnings from Discontinued Operations | 139.81M | 133.28M | -13.37M | -13.37M | -13.37M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 136.00K | -25.48M | -162.11M | -82.68M | -113.72M |
| EBIT | -128.94M | -137.13M | -152.54M | -71.67M | -102.65M |
| EBITDA | -123.47M | -131.11M | -146.25M | -65.27M | -96.41M |
| EPS Basic | -0.03 | -4.54 | -23.63 | -12.00 | -17.82 |
| Normalized Basic EPS | -10.17 | -13.66 | -13.48 | -6.21 | -9.86 |
| EPS Diluted | -0.15 | -4.62 | -23.72 | -12.12 | -17.93 |
| Normalized Diluted EPS | -10.17 | -13.66 | -13.48 | -6.28 | -9.94 |
| Average Basic Shares Outstanding | 31.08M | 29.02M | 27.80M | 26.61M | 25.60M |
| Average Diluted Shares Outstanding | 31.08M | 29.02M | 27.80M | 26.72M | 25.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |